The study evaluated proposed changes to the U.S. childhood hepatitis B vaccination schedule that would affect infants born to women without hepatitis B infection. The baseline strategy was vaccination of every newborn. One alternative was deferred vaccination at two months for infants whose mothers did not have hepatitis B infection, consistent with an Advisory Committee on Immunization Practices recommendation from December 2025. The second alternative used shared decision-making for vaccination at two months among the same group, reflecting a Centers for Disease Control and Prevention proposal from January 2026.

Researchers from Massachusetts General Hospital and Harvard Medical School developed a Markov state-transition model to project the long-term consequences of the three strategies for one birth cohort of 3.6 million infants. The model compared universal vaccination at birth with vaccination deferred to two months and with a shared-decision-making approach at two months. It was not a clinical trial in which infants were assigned to vaccination schedules, and the reported results do not describe outcomes observed under either proposed policy.

The model used chronic hepatitis B infection acquired by age 20 as one principal outcome. It also assessed how many children would enter adulthood vulnerable to hepatitis B infection. Universal birth-dose vaccination served as the reference against which the two proposed alternatives were compared. The release did not provide uncertainty intervals for the reported percentage changes, so the results are best interpreted as projections for the specified strategies and modeled birth cohort rather than precise forecasts of what would occur nationwide.

Deferring the first vaccine dose until age two months for infants born to women without hepatitis B infection was projected to produce a 19% increase in chronic hepatitis B infections acquired by age 20 relative to universal newborn vaccination. This estimate applies to the cohort and policy specification evaluated in the model. The research summary did not report the absolute number of additional infections associated with the projected increase, so the percentage cannot be converted into a reported count of additional cases from the available evidence.

The shared-decision-making strategy yielded the largest projected difference from the birth-vaccination baseline. Under that approach, the model estimated an 83% increase in chronic hepatitis B infections acquired by age 20 compared with vaccinating all newborns. The analysis also projected that more than half of children entering adulthood would be vulnerable to hepatitis B infection. That estimate applies to the shared-decision scenario as modeled; it does not indicate that a majority of U.S. adults are currently vulnerable or that an implemented policy has already produced this outcome.

The contrast between the two alternatives is the central difference in the model results. Deferring vaccination to two months for the specified group was associated with a smaller projected rise in chronic infections, while making the same two-month vaccination contingent on shared decision-making was associated with a substantially larger increase. The release did not report the proportion of parents expected to accept or decline vaccination under the shared-decision strategy, nor did it provide the assumptions used to represent that decision process.

Within the three strategies examined, universal hepatitis B vaccination at birth produced the lowest projected number of chronic infections and the lowest projected adult vulnerability. The authors therefore concluded that universal birth-dose vaccination remained the most effective of the compared strategies for preventing childhood infections and reducing future vulnerability to the virus. This conclusion concerns the model’s comparison of vaccination strategies; the investigators did not directly observe policy outcomes or measure vaccine effectiveness through a prospective or randomized intervention.

The analysis is bounded by several features of the supplied study description. It covered one birth cohort of 3.6 million infants and focused on long-term outcomes through age 20 under specified vaccination policies. The research was a model projection rather than an evaluation of completed vaccination programs, and the news release did not quantify uncertainty around the 19% and 83% percentage changes. It also did not report the model’s full parameter set or provide results for other birth cohorts, regions or schedule scenarios.

The publication examines a specific set of federal policy changes to childhood immunization in the United States. Its scope was the projected effect of changing when or how the first hepatitis B vaccine dose is administered for infants born to women without hepatitis B infection, with chronic infection by age 20 and vulnerability upon entering adulthood as the reported outcomes. The findings quantify modeled differences among the strategies, but they do not establish the causal effects of an implemented policy because all three schedules were evaluated within a model rather than through direct observation of children assigned to each schedule.

The clearest supported result is that the model found a protective advantage for vaccination at birth within the strategies compared. Delaying vaccination to two months was projected to raise chronic infections acquired by age 20 by 19%, while shared decision-making at two months was projected to raise the same measure by 83%. These figures should not be confused with observed national infection trends, completed policy outcomes or clinical recommendations beyond the study. The peer-reviewed modeling article was scheduled to appear in Annals of Internal Medicine on October 20, 2026, following the American College of Physicians news release dated October 19, 2026.

Subject of Research: Modeled effects of proposed U.S. childhood hepatitis B vaccination policy changes on chronic infections by age 20

Article Title: Proposed changes to hepatitis B vaccination schedule could significantly increase infections, model suggests

Article References: Proposed changes to hepatitis B vaccination schedule could significantly increase infections, model suggests. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: hepatitis B, childhood vaccination, birth-dose vaccination, chronic infection, US immunization policy, shared decision-making, Markov model, infectious disease, public health, Proposed, changes, hepatitis